Levy Harkins & Company Cut Position in Novo Nordisk (NVO) by $503,235; Osborne Partners Capital Management Has Lowered Holding in Thermo Fisher Scientific (TMO) by $481,572 as Share Value Rose

April 19, 2018 - By Ellis Scott

Novo Nordisk A/S (NYSE:NVO) Logo

Levy Harkins & Company Inc decreased its stake in Novo Nordisk (NVO) by 3.88% based on its latest 2017Q4 regulatory filing with the SEC. Levy Harkins & Company Inc sold 9,495 shares as the company’s stock declined 9.08% with the market. The hedge fund held 234,980 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $12.61 million, down from 244,475 at the end of the previous reported quarter. Levy Harkins & Company Inc who had been investing in Novo Nordisk for a number of months, seems to be less bullish one the $117.55 billion market cap company. The stock decreased 1.14% or $0.56 during the last trading session, reaching $48.68. About 853,136 shares traded. Novo Nordisk A/S (NYSE:NVO) has risen 42.07% since April 19, 2017 and is uptrending. It has outperformed by 30.52% the S&P500.

Osborne Partners Capital Management Llc decreased its stake in Thermo Fisher Scientific (TMO) by 4.2% based on its latest 2017Q4 regulatory filing with the SEC. Osborne Partners Capital Management Llc sold 2,548 shares as the company’s stock rose 8.51% while stock markets declined. The hedge fund held 58,088 shares of the industrial machinery and components company at the end of 2017Q4, valued at $11.03M, down from 60,636 at the end of the previous reported quarter. Osborne Partners Capital Management Llc who had been investing in Thermo Fisher Scientific for a number of months, seems to be less bullish one the $88.32B market cap company. The stock increased 0.60% or $1.3 during the last trading session, reaching $219.53. About 1.56M shares traded or 7.30% up from the average. Thermo Fisher Scientific Inc. (NYSE:TMO) has risen 33.66% since April 19, 2017 and is uptrending. It has outperformed by 22.11% the S&P500.

Among 15 analysts covering Novo Nordisk (ADR) (NYSE:NVO), 7 have Buy rating, 0 Sell and 8 Hold. Therefore 47% are positive. Novo Nordisk (ADR) had 21 analyst reports since August 28, 2015 according to SRatingsIntel. The stock has “Neutral” rating by JP Morgan on Friday, December 29. The rating was upgraded by HSBC to “Hold” on Wednesday, August 31. On Friday, December 29 the stock rating was upgraded by J.P. Morgan to “Hold”. Bank of America upgraded the stock to “Neutral” rating in Wednesday, September 6 report. DNB Markets downgraded Novo Nordisk A/S (NYSE:NVO) on Monday, October 31 to “Hold” rating. The stock has “Equal-Weight” rating by Morgan Stanley on Thursday, September 1. The firm has “Outperform” rating by BNP Paribas given on Tuesday, September 13. The firm has “Buy” rating given on Friday, January 19 by Goldman Sachs. The rating was initiated by Piper Jaffray with “Neutral” on Friday, September 23. The rating was upgraded by Jyske Bank on Monday, October 19 to “Strong Buy”.

Analysts await Novo Nordisk A/S (NYSE:NVO) to report earnings on May, 2. They expect $0.69 EPS, up 18.97% or $0.11 from last year’s $0.58 per share. NVO’s profit will be $1.67 billion for 17.64 P/E if the $0.69 EPS becomes a reality. After $0.53 actual EPS reported by Novo Nordisk A/S for the previous quarter, Wall Street now forecasts 30.19% EPS growth.

Levy Harkins & Company Inc, which manages about $216.28 million and $322.86 million US Long portfolio, upped its stake in Apple Inc. (NASDAQ:AAPL) by 29,252 shares to 198,454 shares, valued at $33.58 million in 2017Q4, according to the filing.

Among 19 analysts covering Thermo Fisher Scientific (NYSE:TMO), 18 have Buy rating, 0 Sell and 1 Hold. Therefore 95% are positive. Thermo Fisher Scientific had 62 analyst reports since July 24, 2015 according to SRatingsIntel. Robert W. Baird maintained the stock with “Buy” rating in Wednesday, January 31 report. The rating was maintained by Morgan Stanley with “Overweight” on Thursday, February 1. The firm earned “Buy” rating on Thursday, February 1 by Leerink Swann. The firm has “Neutral” rating by Cleveland given on Friday, September 9. The stock has “Hold” rating by Jefferies on Friday, October 20. Mizuho maintained Thermo Fisher Scientific Inc. (NYSE:TMO) on Tuesday, May 3 with “Buy” rating. The firm earned “Hold” rating on Wednesday, September 27 by Jefferies. Cowen & Co maintained Thermo Fisher Scientific Inc. (NYSE:TMO) rating on Wednesday, October 11. Cowen & Co has “Buy” rating and $220.0 target. The stock has “Hold” rating by Jefferies on Tuesday, August 22. As per Thursday, November 10, the company rating was reinitiated by Leerink Swann.

Since December 15, 2017, it had 0 buys, and 8 insider sales for $37.14 million activity. Shares for $211,430 were sold by Parrett William G on Friday, February 23. Shares for $511,511 were sold by Williamson Stephen on Monday, March 5. CASPER MARC N had sold 50,000 shares worth $9.59 million. Herrema Gregory J. sold $7.32M worth of stock or 33,327 shares.

Analysts await Thermo Fisher Scientific Inc. (NYSE:TMO) to report earnings on April, 25 before the open. They expect $2.42 earnings per share, up 16.35% or $0.34 from last year’s $2.08 per share. TMO’s profit will be $973.62M for 22.68 P/E if the $2.42 EPS becomes a reality. After $2.79 actual earnings per share reported by Thermo Fisher Scientific Inc. for the previous quarter, Wall Street now forecasts -13.26% negative EPS growth.

Thermo Fisher Scientific Inc. (NYSE:TMO) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>